Detection of loss of the wild-type P53 gene and kits therefor
AssigneeThe Johns Hopkins University
InventorsBert Vogelstein, Suzanne J. Baker, Eric R. Fearon, Janice M. Nigro
Life of this patent
Estimating the term…
Abstract
Methods and kits are provided for assessing mutations and/or loss of the p53 gene in human tumors. Both deletion mutations and point mutations in p53 are observed in the same human tumor cells and these mutations are clonal within the cells of the tumor. Loss of wild-type p53 genes is responsible for neoplastic progression.
Claims57
A method of determining neoplasia of a tissue of a human, comprising:
- obtaining a first human tissue suspected of being neoplastic,
- comparing p53 genes or p53 transcripts in said first human tissue to wild-type p53 genes or wild-type p53 transcripts having a size of about 2.8 kb, said wild-type p53 genes or transcripts being defined by their presence in normal human tissues, an observed difference between p53 genes or p53 transcripts in the first tissue of said human and wild-type indicating neoplasia of the tissue.
An allele-specific nucleic acid probe consisting of the nucleic acid sequence of a region of a human mutant p53 gene or its ribonucleotide equivalent, said region containing a mutation.
A method of detecting the presence of a neoplastic tissue in a human, comprising:
- obtaining a body sample isolated from a human;
- comparing p53 genes or p53 transcripts in the body sample to a wild-type p53 gene or wild-type p53 transcripts having a size of about 2.8 kb, said wild-type p53 gene or transcripts being defined by their presence in normal human tissues, an observed difference between the p53 genes or p53 transcripts in the body sample and wild-type indicating the presence of a neoplastic tissue in the human.
A method of detecting genetic predisposition to cancer in a human, comprising:
- extracting DNA from a human sample selected from the group consisting of blood and fetal tissue;
- comparing a p53 gene in said DNA to a wild-type p53 gene, said wild-type p53 gene being defined by its presence in normal human tissues, an observed difference between the p53 genes indicating a predisposition to cancer in the human.
A method of determining neoplasia of a tissue of a human, comprising:
- obtaining a first human tissue suspected of being neoplastic;
- comparing p53 genes or p53 transcripts in the first human tissue to wild-type p53 genes or wild-type p53 transcripts having a size of about 2.8 kb, said wild-type p53 genes or transcripts being defined by their presence in normal tissues of said human, an observed difference between the p53 genes or p53 transcripts indicating neoplasia.
A kit for determination of the nucleotide sequence of a p53 gene by polymerase chain reaction, comprising:
- a pair of single stranded DNA primers, said pair allowing synthesis of wild-type p53 gene coding sequences;
- and
- an allele-specific nucleic acid probe consisting of the nucleic acid sequence of a region of a human mutant p53 gene or its ribonucleotide equivalent, said region containing a mutation.
A kit for determination of the nucleotide sequence of a p53 gene by polymerase chain reaction, comprising:
- a set of pairs of single stranded DNA primers, said set allowing synthesis of all nucleotides of the wild-type p53 gene coding sequences;
- and
- an allele-specific nucleic acid probe consisting of the nucleic acid sequence of a region of a human mutant p53 gene or its ribonucleotide equivalent, said region containing a mutation.
Dependencies are inferred from the claim text.